Defucosylated Anti-CD44 Monoclonal Antibodies Exert Antitumor Activities against Esophageal Tumor Xenograft
K Ishikawa, H Suzuki, T Ohishi, A Ohkoshi, MK Kaneko… - 2024
CD44 is a type I transmembrane glycoprotein, which is associated with poor
prognosis in various solid tumors. Since CD44 plays critical roles in tumor
development by regulating cell adhesion, survival, proliferation, and stemness, it has
been considered a target for tumor therapy. Anti-CD44 monoclonal antibodies
(mAbs) have been developed and applied to antibody-drug conjugates and chimeric
antigen receptor-T cell therapy. We previously developed anti‐pan-CD44 mAbs, C …
prognosis in various solid tumors. Since CD44 plays critical roles in tumor
development by regulating cell adhesion, survival, proliferation, and stemness, it has
been considered a target for tumor therapy. Anti-CD44 monoclonal antibodies
(mAbs) have been developed and applied to antibody-drug conjugates and chimeric
antigen receptor-T cell therapy. We previously developed anti‐pan-CD44 mAbs, C …
| • | 引用: Antitumor activities of a defucosylated anti‑EpCAM monoclonal …  |
 |
 |
 |
 |
[PDF] Updates in BRAF V600E-Mutated Metastatic Colorectal Cancer
F Paris-Cité - EMJ, 2024
BRAF V600E-mutated mCRC. The importance of surgery in the multidisciplinary
management of patients with BRAF V600E-mutated mCRC, BRAF as a prognostic
marker in resected CRC, and real-world studies in this field were also explored.
Finally, Cremolini and Taieb described what the future of the management of patients
with BRAF V600E-mutated mCRC might look like, and which advancements in
research they would like to see.
management of patients with BRAF V600E-mutated mCRC, BRAF as a prognostic
marker in resected CRC, and real-world studies in this field were also explored.
Finally, Cremolini and Taieb described what the future of the management of patients
with BRAF V600E-mutated mCRC might look like, and which advancements in
research they would like to see.
| • | 引用: Current targeted therapy for metastatic colorectal cancer |
|
|
|
|
Unleashing a Dual‐Warhead Nanomedicine to Precisely Sensitize Immunotherapy for Pancreatic Ductal Adenocarcinoma
D Zhang, Q Song, W Wang, Q Li, Z Zhao, Y Jiang… - Advanced Functional …, 2024
Despite remarkable achievements in cancer immunotherapy, significant challenges
persist in pancreatic ductal adenocarcinoma (PDAC) treatment. Particularly, there is
a critical issue of inadequate intratumoral infiltration of effector T cells, primarily
attributed to the physical “hard” barrier caused by extracellular matrix (ECM) and the
“soft” barrier imposed by immune suppression. Here, a dual‐warhead nanomedicine
is reported that effectively targets and attacks the barriers to precisely sensitize …
persist in pancreatic ductal adenocarcinoma (PDAC) treatment. Particularly, there is
a critical issue of inadequate intratumoral infiltration of effector T cells, primarily
attributed to the physical “hard” barrier caused by extracellular matrix (ECM) and the
“soft” barrier imposed by immune suppression. Here, a dual‐warhead nanomedicine
is reported that effectively targets and attacks the barriers to precisely sensitize …
| • | 引用: BACH1 promotes pancreatic cancer metastasis by repressing … |